Patents by Inventor Christopher K. Breuer
Christopher K. Breuer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10895020Abstract: A method for generating a electro spun fiber medical implant including determining dimensions of a portion of anatomy of a patient corresponding to the electro spun fiber medical implant via medical imaging, generating a model of the portion of the anatomy based on the dimensions, the model including one or more solid areas and one or more void areas encompassed within the one or more solid areas, inverting the model to generate a mandrel model, the mandrel model generated based on the one or more void areas, generating the mandrel based on the mandrel model, the mandrel including at least one electrically conductive material therein, and applying an electro-spinning process to the mandrel to generate the electro spun fiber medical implant which circumscribes the mandrel, wherein the mandrel is removable from within the electro spun fiber medical implant after a disassembly process.Type: GrantFiled: August 26, 2016Date of Patent: January 19, 2021Assignees: CHILDREN'S NATIONAL MEDICAL CENTER, RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL, NANOFIBER SOLUTIONS LLCInventors: Axel Krieger, Narutoshi Hibino, Jed Johnson, Justin Opfermann, Carolyn Cochenour Dorgan, Christopher K. Breuer
-
Patent number: 10300082Abstract: A composition containing a macrophage inhibitor may be administered in an effective amount to prevent, inhibit or reduce restenosis, thrombus or aneurysm formation in implanted polymeric vascular grafts. The composition may be administered prior to vascular graft implantation, at the same time as vascular graft implantation, following vascular graft implantation, or any combination thereof. Examplary macrophage inhibitors include bisphosphonates, anti-folate drugs and antibodies, preferably in a controlled release or liposomal formulation.Type: GrantFiled: April 13, 2016Date of Patent: May 28, 2019Assignee: Yale UniversityInventors: Christopher K. Breuer, Tarek Fahmy
-
Publication number: 20180245243Abstract: A method for generating a electro spun fiber medical implant including determining dimensions of a portion of anatomy of a patient corresponding to the electro spun fiber medical implant via medical imaging, generating a model of the portion of the anatomy based on the dimensions, the model including one or more solid areas and one or more void areas encompassed within the one or more solid areas, inverting the model to generate a mandrel model, the mandrel model generated based on the one or more void areas, generating the mandrel based on the mandrel model, the mandrel including at least one electrically conductive material therein, and applying an electro-spinning process to the mandrel to generate the electro spun fiber medical implant which circumscribes the mandrel, wherein the mandrel is removable from within the electro spun fiber medical implant after a disassembly process.Type: ApplicationFiled: August 26, 2016Publication date: August 30, 2018Applicants: CHILDREN'S NATIONAL MEDICAL CENTER, RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL, NANOFIBER SOLUTIONSInventors: Axel KRIEGER, Narutoshi HIBINO, Jed JOHNSON, Justin OPFERMANN, Carolyn COCHENOUR, Christopher K. BREUER
-
Publication number: 20160271152Abstract: A composition containing a macrophage inhibitor may be administered in an effective amount to prevent, inhibit or reduce restenosis, thrombus or aneurysm formation in implanted polymeric vascular grafts. The composition may be administered prior to vascular graft implantation, at the same time as vascular graft implantation, following vascular graft implantation, or any combination thereof. Examplary macrophage inhibitors include bisphosphonates, anti-folate drugs and antibodies, preferably in a controlled release or liposomal formulation.Type: ApplicationFiled: April 13, 2016Publication date: September 22, 2016Inventors: Christopher K. Breuer, Tarek Fahmy
-
Patent number: 9326951Abstract: A composition containing a macrophage inhibitor may be administered in an effective amount to prevent, inhibit or reduce restenosis, thrombus or aneurysm formation in implanted polymeric vascular grafts. The composition may be administered prior to vascular graft implantation, at the same time as vascular graft implantation, following vascular graft implantation, or any combination thereof. Exemplary macrophage inhibitors include bisphosphonates, anti-folate drugs and antibodies, preferably in a controlled release or liposomal formulation.Type: GrantFiled: June 20, 2012Date of Patent: May 3, 2016Assignee: Yale UniversityInventors: Christopher K. Breuer, Tarek Fahmy
-
Publication number: 20140147484Abstract: A composition containing a macrophage inhibitor may be administered in an effective amount to prevent, inhibit or reduce restenosis, thrombus or aneurysm formation in implanted polymeric vascular grafts. The composition may be administered prior to vascular graft implantation, at the same time as vascular graft implantation, following vascular graft implantation, or any combination thereof. Examplary macrophage inhibitors include bisphosphonates, anti-folate drugs and antibodies, preferably in a controlled release or liposomal formulation.Type: ApplicationFiled: June 20, 2012Publication date: May 29, 2014Applicant: YALE UNIVERSITYInventors: Christopher K. Breuer, Tarek Fahmy
-
Patent number: 6348069Abstract: It has been discovered that improved yields of engineered tissue following implantation, and engineered tissue having enhanced mechanical strength and flexibility or pliability, can be obtained by implantation, preferably subcutaneously, of a fibrous polymeric matrix for a period of time sufficient to obtain ingrowth of fibrous tissue and/or blood vessels, which is the removed for subsequent implantation at the site where the implant is desired. The matrix is optionally seeded prior to the first implantation, after ingrowth of the fibrous tissue, or at the time of reimplantation. The time required for fibrous ingrowth typically ranges from days to weeks. The method is particularly useful in making valves and tubular structures, especially heart valves and blood vessels.Type: GrantFiled: November 3, 1998Date of Patent: February 19, 2002Assignee: Children's Medical Center CorporationInventors: Joseph P. Vacanti, Christopher K. Breuer, Beverly E. Chaignaud, Toshiraru Shin'oka
-
Patent number: 5855610Abstract: It has been discovered that improved yields of engineered tissue following implantation, and engineered tissue having enhanced mechanical strength and flexibility or pliability, can be obtained by implantation, preferably subcutaneously, of a fibrous polymeric matrix for a period of time sufficient to obtain ingrowth of fibrous tissue and/or blood vessels, which is the removed for subsequent implantation at the site where the implant is desired. The matrix is optionally seeded prior to the first implantation, after ingrowth of the fibrous tissue, or at the time of reimplantation. The time required for fibrous ingrowth typically ranges from days to weeks. The method is particularly useful in making valves and tubular structures, especially heart valves and blood vessels.Type: GrantFiled: May 19, 1995Date of Patent: January 5, 1999Assignee: Children's Medical Center CorporationInventors: Joseph P. Vacanti, Christopher K. Breuer, Beverly E. Chaignaud, Toshiraru Shin'oka
-
Patent number: RE42479Abstract: It has been discovered that improved yields of engineered tissue following implantation, and engineered tissue having enhanced mechanical strength and flexibility or pliability, can be obtained by implantation, preferably subcutaneously, of a fibrous polymeric matrix for a period of time sufficient to obtain ingrowth of fibrous tissue and/or blood vessels, which is the removed for subsequent implantation at the site where the implant is desired. The matrix is optionally seeded prior to the first implantation, after ingrowth of the fibrous tissue, or at the time of reimplantation. The time required for fibrous ingrowth typically ranges from days to weeks. The method is particularly useful in making valves and tubular structures, especially heart valves and blood vessels.Type: GrantFiled: February 19, 2004Date of Patent: June 21, 2011Assignee: Children's Medical Center CorporationInventors: Joseph P. Vacanti, Christopher K. Breuer, Berverly E. Chaignaud, Toshiraru Shin'oka
-
Patent number: RE42575Abstract: It has been discovered that improved yields of engineered tissue following implantation, and engineered tissue having enhanced mechanical strength and flexibility or pliability, can be obtained by implantation, preferably subcutaneously, of a fibrous polymeric matrix for a period of time sufficient to obtain ingrowth of fibrous tissue and/or blood vessels, which is the removed for subsequent implantation at the site where the implant is desired. The matrix is optionally seeded prior to the first implantation, after ingrowth of the fibrous tissue, or at the time of reimplantation. The time required for fibrous ingrowth typically ranges from days to weeks. The method is particularly useful in making valves and tubular structures, especially heart valves and blood vessels.Type: GrantFiled: September 28, 2006Date of Patent: July 26, 2011Assignee: Children's Medical Center CorporationInventors: Joseph P. Vacanti, Christopher K. Breuer, Berverly E. Chaignaud, Toshiraru Shin'oka